(E)-methyl 7-(3,7-dimethylocta-2,6-dienyloxy)-2-oxo-2H-chromene-3-carboxylate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (E)-methyl 7-(3,7-dimethylocta-2,6-dienyloxy)-2-oxo-2H-chromene-3-carboxylate
• 英文别名: methyl 7-[(2E)-3,7-dimethylocta-2,6-dienoxy]-2-oxochromene-3-carboxylate
• 化学式: C₂₁H₂₄O₅
• 分子量: 356.419
• InChiKey: HMADAONXXOTVPK-XNTDXEJSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-methyl 7-(3,7-dimethylocta-2,6-dienyloxy)-2-oxo-2H-chromene-3-carboxylate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 生成 (E)-7-(3,7-dimethylocta-2,6-dienyloxy)-2-oxo-2H-chromene-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells

  摘要：

  Under hypoxia, cancer cells consume glucose and release lactate at a high rate. Lactate was recently documented to be recaptured by oxygenated cancer cells to fuel the TCA cycle and thereby to support tumor growth. Monocarboxylate transporters (MCT) are the main lactate carriers and therefore represent potential therapeutic targets to limit cancer progression. In this study, we have developed and implemented a stepwise in vitro screening procedure on human cancer cells to identify new potent MCT inhibitors. Various 7-substituted carboxycoumarins and quinolinone derivatives were synthesized and pharmacologically evaluated. Most active compounds were obtained using a palladium-catalyzed Buchwald-Hartwig type coupling reaction, which proved to be a quick and efficient method to obtain aminocarboxycoumarin derivatives. Inhibition of lactate flux revealed that the most active compound 19 (IC50 11 nM) was three log orders more active than the CHC reference compound. Comparison with warfarin, a conventional anticoagulant coumarin, further showed that compound 19 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as anticancer drugs through inhibition of lactate flux. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.09.010
• 作为产物：
  描述：

  2,4-二羟基苯甲醛 在 哌啶 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 (E)-methyl 7-(3,7-dimethylocta-2,6-dienyloxy)-2-oxo-2H-chromene-3-carboxylate
  参考文献：
  名称：

  炔基-香豆基醚作为MAO-B抑制剂

  摘要：

  在这项研究中，开发了炔基-香豆基醚作为人单胺氧化酶B（MAO-B）的抑制剂。通过羟基香豆素合成了31种新的，与醚连接的香豆素衍生物，该羟基香豆素的6、7或8位酚基通过Mitsunobu反应转化。大多数最终产品是由带有末端炔基的伯醇生产的。就炔基氧基链的结构及其在稠合苯环上的位置以及吡喃-2 H-一部分的3位上的残基而言，对抑制剂进行了优化。发现在位置7的六-5-炔氧基链是特别有利的。在7-己-5-炔氧基香豆素中，3-甲氧基羰基衍生物36被表征为具有IC的双作用抑制剂对MAO-A和MAO-B的50个值小于10 nM，并且3-（4-甲氧基）苯基衍生物44被证明具有强大的抗MAO-B效力（IC 50  = 3.0 nM）和对MAO的选择性-B高于MAO-A（选择性> 3400倍）。

  DOI：

  10.1016/j.bmc.2014.01.046

文献信息

• 3-CARBOXY SUBSTITUTED COUMARIN DERIVATIVES WITH A POTENTIAL UTILITY FOR THE TREATMENT OF CANCER DISEASES
  申请人：UNIVERSITE CATHOLIQUE DE LOUVAIN

  公开号：US20160115146A1

  公开（公告）日：2016-04-28

  The present invention relates to novel compounds. The present invention also relates to the compounds for use as a medicine, more in particular for the prevention or treatment of cancer, more in particular cancers expressing MCT1 and/or MCT4. The present invention also relates to a method for the prevention or treatment of cancer in animals or humans by using the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds and to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of cancer. The present invention also relates to processes for the preparation of the compounds.

  本发明涉及新颖化合物。本发明还涉及用于药物的化合物，更具体地用于预防或治疗癌症，更具体地用于表达MCT1和/或MCT4的癌症。本发明还涉及使用新颖化合物预防或治疗动物或人类癌症的方法。本发明还涉及新颖化合物的制药组合物或复方制剂，以及用于药物的组合物或制剂，更优选用于预防或治疗癌症。本发明还涉及制备这些化合物的方法。
• Alkynyl–coumarinyl ethers as MAO-B inhibitors
  作者：Matthias D. Mertens、Sonja Hinz、Christa E. Müller、Michael Gütschow

  DOI：10.1016/j.bmc.2014.01.046

  日期：2014.3

  In this study, alkynyl–coumarinyl ethers were developed as inhibitors of human monoamine oxidase B (MAO-B). A series of 31 new, ether-connected coumarin derivatives was synthesized via hydroxycoumarins, whose phenolic group at position 6, 7 or 8 was converted by means of the Mitsunobu reaction. The majority of the final products were produced from primary alcohols with a terminal alkyne group. The

  在这项研究中，开发了炔基-香豆基醚作为人单胺氧化酶B（MAO-B）的抑制剂。通过羟基香豆素合成了31种新的，与醚连接的香豆素衍生物，该羟基香豆素的6、7或8位酚基通过Mitsunobu反应转化。大多数最终产品是由带有末端炔基的伯醇生产的。就炔基氧基链的结构及其在稠合苯环上的位置以及吡喃-2 H-一部分的3位上的残基而言，对抑制剂进行了优化。发现在位置7的六-5-炔氧基链是特别有利的。在7-己-5-炔氧基香豆素中，3-甲氧基羰基衍生物36被表征为具有IC的双作用抑制剂对MAO-A和MAO-B的50个值小于10 nM，并且3-（4-甲氧基）苯基衍生物44被证明具有强大的抗MAO-B效力（IC 50  = 3.0 nM）和对MAO的选择性-B高于MAO-A（选择性> 3400倍）。
• Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells
  作者：Nihed Draoui、Olivier Schicke、Antony Fernandes、Xavier Drozak、Fady Nahra、Amélie Dumont、Jonathan Douxfils、Emmanuel Hermans、Jean-Michel Dogné、Romu Corbau、Arnaud Marchand、Patrick Chaltin、Pierre Sonveaux、Olivier Feron、Olivier Riant

  DOI：10.1016/j.bmc.2013.09.010

  日期：2013.11

  Under hypoxia, cancer cells consume glucose and release lactate at a high rate. Lactate was recently documented to be recaptured by oxygenated cancer cells to fuel the TCA cycle and thereby to support tumor growth. Monocarboxylate transporters (MCT) are the main lactate carriers and therefore represent potential therapeutic targets to limit cancer progression. In this study, we have developed and implemented a stepwise in vitro screening procedure on human cancer cells to identify new potent MCT inhibitors. Various 7-substituted carboxycoumarins and quinolinone derivatives were synthesized and pharmacologically evaluated. Most active compounds were obtained using a palladium-catalyzed Buchwald-Hartwig type coupling reaction, which proved to be a quick and efficient method to obtain aminocarboxycoumarin derivatives. Inhibition of lactate flux revealed that the most active compound 19 (IC50 11 nM) was three log orders more active than the CHC reference compound. Comparison with warfarin, a conventional anticoagulant coumarin, further showed that compound 19 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as anticancer drugs through inhibition of lactate flux. (C) 2013 Elsevier Ltd. All rights reserved.